PATHOS : A Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516673-68-00

Acronym

SPON1610-17

Enrollment

240

Registered

2025-01-16

Start date

2020-10-27

Completion date

Unknown

Last updated

2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human papillomavirus (HPV)-positive oropharyngeal cancer

Brief summary

Overall survival and swallowing function as measured by the MD Anderson Dysphagia Inventory (MDADI) score.

Detailed description

Swallowing panel measurements including qualitative and quantitative swallowing assessments as described previously., QOL (using EORTC QLQ C30 and HN35 questionnaires)., Acute and late toxicity, assessed using NCI CTCAE criteria version 4.03, Overall survival, disease free survival, locoregional control, distant metastases.

Interventions

DRUGCISPLATIN

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival and swallowing function as measured by the MD Anderson Dysphagia Inventory (MDADI) score.	—

Secondary

Measure	Time frame
Swallowing panel measurements including qualitative and quantitative swallowing assessments as described previously., QOL (using EORTC QLQ C30 and HN35 questionnaires)., Acute and late toxicity, assessed using NCI CTCAE criteria version 4.03, Overall survival, disease free survival, locoregional control, distant metastases.	—

Countries

France, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026